News Hub | News Direct

Communications

Advertising Communications Graphic Design Internet Marketing Media Publishing SEO
Article thumbnail News Release

BestGrowthStocks.Com Issues Extensive Comprehensive Analysis of Phunware Inc

PHUNWARE

NEW YORK, NY / NewsDirect / October 24th, 2024 / Best Growth Stocks, a leading independent equity research and corporate access firm focused on finding and reporting on the best growth stocks utilizing exclusive ai-assisted research recently issued an in-depth analysis of Phunware Inc. a leader in enterprise cloud solutions for mobile applications. Phunware Inc. (NASDAQ: PHUN) has garnered significant investor attention following their entry into generative AI. Best Growth Stock's full report offers an in-depth analysis of Phunware’s recent announcement, short interest, current share structure according to dilution tracker, cash position and runway, potential catalysts, growth drivers, financials and more. Access this full analysis free here: https://bestgrowthstocks.com/access-phunware-analysis-phun/ About Phunware, Inc. Phunware, Inc. (NASDAQ: PHUN) is an enterprise software company specializing in mobile app solutions. We provide businesses with the tools to create, implement, and manage custom mobile applications and analytics, digital advertising, and location-based services. Phunware is transforming mobile engagement by delivering scalable and personalized mobile app experiences.  Phunware’s mission is to achieve unparalleled connectivity and monetization through widespread adoption of Phunware mobile technologies by leveraging brands, consumers, partners, and digital asset holders and market participants. Phunware is poised to expand its software products and services audience and industry verticals through its new platform, utilize and monetize its patents and other intellectual property rights and interests, and update and reintroduce its digital asset ecosystem for existing holders and new market participants.  For more information, please visit www.ai.phunware.com About Best Growth Stocks Best Growth Stocks is a leading independent equity research and corporate access firm focused on finding and reporting the best growth stocks utilizing our exclusive ai-assisted research. BGS is also a financial news provider, focused on giving investors direct access to CEOs of promising, publicly-traded companies, and market experts. Our CEO interviews aim to answer the questions that rest on the minds of current and future shareholders. This is not to be construed as financial advice. Please consult with a licensed financial advisor before making any investment decisions. Media Contact Best Growth Stocks Senior Editor: Steve Macalbry Editor@BestGrowthStocks.Com SOURCE: BestGrowthStocks.Com Contact Details Best Growth Stocks Steve Macalbry Editor@bestgrowthstocks.com Company Website https://bestgrowthstocks.com/

October 24, 2024 07:00 AM Eastern Daylight Time

Article thumbnail News Release

Investor Releases Satirical Video Calling for Reid Hoffman’s Removal from Microsoft’s Board

NLPC

Poor judgment that led him to visit [Jeffrey] Epstein Island, asking friends to meet with the late pedophile, and an overwrought obsession with the defeat and downfall of President Trump, are just a few of the reasons why tech investor Reid Hoffman should no longer serve on Microsoft’s board of directors, according to an investor in the company. And now that shareholder, National Legal and Policy Center, has released a satirical video to amplify the case it has made for the last 18 months – that the LinkedIn co-founder is unfit for such a prestigious role with the software giant. Last year NLPC submitted a memorandum to the Securities and Exchange Commission asking shareholders to vote against Hoffman’s re-election to the Microsoft board. The nonprofit investor again called for his removal this year in an additional filing at the SEC, after he told fellow billionaire elites at a Sun Valley, Idaho conference that he wished he had made Donald Trump an “actual martyr,” just days before an assassination attempt was made on the former President in Butler, Pa. “There are plenty of active and generous donors, mostly to left-leaning candidates, on corporate boards in the U.S., but we don’t consider them unfit to serve,” said Paul Chesser, director of NLPC’s Corporate Integrity Project. “But with his excessive Trump obsession, dubious political ethics and funding of lawfare, Reid Hoffman is in another class, which should eliminate him from consideration for any public company leadership role.” Microsoft’s annual meeting is scheduled for December 10, and release of the company’s proxy statement is expected before the end of October. Watch NLPC’s video on Hoffman and his role at Microsoft here. For more information or to schedule an interview with Paul Chesser, contact Dan Rene at 202-329-8357 or drene@nlpc.org. Please visit http://www.nlpc.org. Founded in 1991, the National Legal and Policy Center promotes ethics in public life through research, investigation, education and legal action. Contact Details National Legal and Policy Center Dan Rene +1 202-329-8357 drene@nlpc.org Company Website http://www.nlpc.org

October 16, 2024 03:00 PM Eastern Daylight Time

Article thumbnail News Release

Silexion Therapeutics to Present at 2024 Maxim Healthcare Virtual Summit

Silexion Therapeutics Corp

Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven cancers, today announced its participation in the 2024 Maxim Healthcare Virtual Summit, scheduled to take place from October 15 to 17, 2024. Ilan Hadar, Chief Executive Officer and Dr. Mitchell Shirvan, Chief Scientific and Development Officer will join a fireside chat hosted by Jason McCarthy, Senior Managing Director and Head of Biotechnology Research at Maxim Group, on Thursday, October 17, 2024, at 9:30am ET. The event will be streamed live on M-Vest and accessible to members by clicking here or via following link: https://m-vest.com/events/healthcare-10152024. The Company’s management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting. About Silexion Therapeutics: Silexion Therapeutics (NASDAQ: SLXN) is a pioneering clinical-stage, oncology-focused biotechnology company developing innovative RNA interference (RNAi) therapies to treat solid tumors driven by KRAS mutations, the most common oncogenic driver in human cancers. The company's first-generation product, LODER™, has shown promising results in a Phase 2 trial for non-resectable pancreatic cancer. Silexion is also advancing its next-generation siRNA candidate, SIL-204, designed to target a broader range of KRAS mutations and showing significant potential in preclinical studies. The company remains committed to pushing the boundaries of therapeutic innovation in oncology, with a focus on improving outcomes for patients with difficult-to-treat cancers. For more information please visit: https://silexion.com Contact Details Silexion Therapeutics Corp Ms. Mirit Horenshtein Hadar, CFO mirit@silexion.com ARX | Capital Markets Advisors North American Equities Desk silexion@arxadvisory.com

October 09, 2024 04:30 PM Eastern Daylight Time

Article thumbnail News Release

Kevel partners with the World’s Largest Home Improvement Retailer to in-house its retail media technology for Orange Apron Media

Kevel

Both Kevel and Orange Apron Media share a common goal: advertising partner success. They understand that having a tangible impact on their partners’ businesses and success transcends traditional revenue goals and emphasizes a symbiotic relationship where growth is intrinsically tied to the prosperity of their clients. While the partnership between Kevel and Orange Apron Media has just officially launched, it promises to continue to bring innovation to the retail media landscape. Kevel, the API-first ad serving company, is formally announcing its partnership with The Home Depot to support its in-house transformation of its retail media network’s, Orange Apron Media Technology. After six years of providing home improvement retail media solutions, Orange Apron Media embarked on a new journey of transformation and innovation. The Orange Apron Media team will rely on Kevel's Retail Media Cloud™ to power its in-house journey as the company continues to transform and innovate its services. As the home improvement retailer looked to lean further into their competitive edge as a specialty retailer, continuing to innovate their retail media offerings and capabilities for advertisers, they knew flexibility and innovation would be vital. Orange Apron Media turned to Kevel’s flexible, API-based Retail Media Cloud TM solution to power its in-house retail media technology. With the addition of Kevel’s Retail Media Cloud TM, Orange Apron Media built a differentiated retail media network and added value to its ad products by enabling advertisers to connect with customers closer to the point of purchase. Working closely with the Kevel team to upgrade its in-house retail media technology, the Orange Apron Media team will continue to double down on its goal to provide advertisers with value and performance. Through this collaboration Orange Apron Media and Kevel will continue to seamlessly integrate retail media offerings into its digital strategies, emphasizing enhancements to the customer experience across both owned and off-site channels through storytelling and personalization leveraging unique first-party data. “Providing the best possible service and experience for our customers and our advertising partners is at the top of our list of priorities,” said Melanie Babcock, vice president of Orange Apron Media and Monetization. “Finding like-minded partners, like Kevel, makes it easier to build custom solutions that help brands connect with customers at the right place and at the right time. When customization is done right, it enhances everyone’s experience.” Both Kevel and Orange Apron Media are dedicated to enhancing their solutions through innovation and continue to stay at the forefront of the constantly evolving digital advertising landscape, making the partnership an excellent fit at a pivotal time in the industry. Kevel continues to stand out amongst ad tech solution providers as the only API-based solution for in-housing retail media technology, allowing retailers to differentiate based on their unique brand and first-party data. Orange Apron Media is forging the path for specialty retailers by developing an enhanced omnichannel customer experience through ads that tell a story across the customer journey, ensuring their advertisers receive at least two-times return on their ad spend. “There has been a large shift in the retail media landscape as brands focus on the retail media networks that deliver real value versus those that are commoditized and not fit for purpose. This is pushing retailers to move from off the shelf solutions to build high-end, differentiated retail media networks,” says James Avery, Founder & CEO Kevel. “Kevel’s flexible API-based Retail Media Cloud was designed specifically to enable retailers like Orange Apron to build customized in-house retail media solutions in a way that really differentiates them, leveraging their unique attributes to provide advertisers with innovative, cutting edge decisioning, ad formats, targeting, and site performance, all while keeping their data safe and secure at scale.” About Kevel Kevel is powering innovative, flexible ad tech infrastructure APIs that fuel its Retail Media Cloud™. This unique offering is the only API-based solution for in-housing retail media technology that enables multi-brand retailers to differentiate based on their unique brand, improving shopper experience while maintaining total control of their first-party data.Kevel believes that every digital retailer should have the capability to build and scale their own distinct ad platform, just like big tech players like Amazon. Customers like Edmunds, Delivery Hero, Sonae, Leroy Merlin, Slickdeals, and other leading retailers and marketplaces all launched their own retail media networks with Kevel.The company has garnered numerous accolades, most recently earning recognition as one of the leading 100 innovative tech start-ups driving the future of brand-to-consumer in 2023 and awarded the MarTech Breakthrough Award for best overall ad tech company in 2022. Learn more at www.kevel.com About Orange Apron Media The Home Depot Retail Media network offers businesses like yours the opportunity to connect with consumers like never before. Regardless of your budget, we have a solution to meet your marketing needs. Choose one of our advertising offerings or mix and match to find what is right for your company and your specific products. The Home Depot advertising department leverages a myriad of online and offline channels to spread awareness of your brand and promote your products. From email advertising to social media branded marketing, these solutions are designed to propel your business and help increase sales. The Home Depot's advertising center tracks customer interest via our website, enabling us to promote your brand through retargeted ads and other off-site channels to keep your products top of mind. Retail advertising is key to setting yourself apart from competitors in an ever-changing market. About The Home Depot The Home Depot is the world's largest home improvement specialty retailer. At the end of the first quarter, the company operated a total of 2,324 retail stores in all 50 states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico. The company employs approximately 475,000 associates. The Home Depot's stock is traded on the New York Stock Exchange (NYSE: HD) and is included in the Dow Jones industrial average and Standard & Poor's 500 index. The Home Depot is #17 on the 2022 Fortune 500. Contact Details Kevel Jennifer Choo, Director of Marketing +1 973-343-8819 jchoo@kevel.com

October 08, 2024 09:00 AM Eastern Daylight Time

Article thumbnail News Release

NAVEX Unveils Curated AI Content Library to Simplify Compliance and Risk Mitigation

NAVEX Global

NAVEX, the global leader in integrated risk and compliance management software, introduces its new AI-focused content library designed to help organizations address the rapidly evolving landscape of Artificial Intelligence (AI) regulations and frameworks. As AI technologies become part of daily operations, many organizations find themselves entering uncharted waters regarding effective AI governance. According to Forrester’s September 2023 Artificial Intelligence Pulse Survey, 56% of AI decision-makers said their organization will use generative AI (genAI) in the next 12 months for internal or customer-facing production applications for employee productivity. The stakes are rising, and navigating these challenges without a clear framework can feel overwhelming, leaving companies vulnerable to risks. NAVEX plays a critical role by enabling companies to implement strong controls, automate workflows, and perform comprehensive testing. This approach simplifies complex challenges and transforms them into strategic opportunities. NAVEX’s content library is continuously curated to cover international and industry-specific AI regulations, including emerging standards and compliance requirements. By leveraging this resource, customers can ensure their AI initiatives align with ethical guidelines and regulatory mandates. A.G. Lambert, Chief Product Officer at NAVEX, captures the pivotal moment many organizations face: "As AI technologies revolutionize industries, companies find themselves standing at a crossroads, navigating the intricate landscape of effective AI governance. Our AI content not only empowers risk management professionals to establish crucial controls but also enhances efficiency by automating compliance processes. This dual approach enables organizations to embrace AI technology with confidence, transforming challenges into opportunities for growth and innovation." Key features of the NAVEX AI content library include: Centralized AI Regulatory Resources: Access a consolidated library of global AI regulations and industry-specific guidelines. Streamlined Control Development: Simplify the process of creating and implementing AI-specific controls to align with emerging regulations. Automated Compliance Monitoring: Leverage automation to track compliance requirements and ensure adherence through continuous control testing. Enhanced Risk Mitigation: Identify and mitigate AI-related risks proactively using structured regulatory frameworks. Future-Proof Compliance Strategy: Stay ahead of evolving AI laws and standards, ensuring the organization remains compliant and competitive. NAVEX is enhancing AI governance with its NAVEX One platform that streamlines the process of developing and distributing AI-related policies, ensuring companies stay aligned with fast-changing compliance requirements in the AI landscape. Should employees or third parties have AI-related issues or concerns, the NAVEX One platform offers employees a secure solution to report them. This proactive approach helps organizations identify and mitigate potential risks early on. The NAVEX content library offers over 400 regulations and compliance frameworks, continuously expanding to meet the demands of an evolving regulatory environment. This extensive resource includes critical AI regulations such as the EU AI Act, NIST AI Risk Management Framework, and the Colorado Artificial Intelligence Act. As AI governance becomes increasingly critical, NAVEX integrates AI training, incident management, and policy management into this comprehensive resource, ensuring organizations stay ahead of compliance requirements. With real-time updates, businesses can select tailored content to meet emerging AI regulatory standards, providing the tools to navigate current and future compliance challenges effectively. This seamless integration helps organizations maintain a proactive risk and compliance posture while leveraging cutting-edge technologies. The new AI content library is now available as part of NAVEX’s Integrated Risk Management solution. For more information, visit NAVEX’s Website. NAVEX is trusted by thousands of customers worldwide to help them achieve the business outcomes that matter most. As the global leader in integrated risk and compliance management software and services, we deliver solutions through the NAVEX One platform, the industry’s most comprehensive governance, risk and compliance (GRC) information system. For more information, visit NAVEX.com and our blog. Follow us on Twitter and LinkedIn. Contact Details Navex Global +1 617-388-5773 scott.levesque@navex.com Company Website https://navex.com

October 08, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

Market Alert: Silexion Therapeutics (NASDAQ: SLXN) Sees Record Volumes Following Breakthrough Preclinical Data for SIL-204

Global Markets News

Shares of Silexion Therapeutics (NASDAQ:SLXN) are seeing significatnly today after the company announced promising new preclinical data for its next-generation siRNA candidate, SIL-204. The stock saw a significant initial of price spike of over 50% in pre-market activity as investors responded to the latest developments in Silexion's RNA interference (RNAi) platform, which targets KRAS-driven cancers. As of now, volume is at record highs, currently standing at over 50 million shares today. The company revealed that SIL-204, an extended-release microparticle formulation, demonstrated substantial tumor reduction and necrosis in mouse models of pancreatic cancer bearing the KRAS G12D mutation—one of the most common mutations found in pancreatic cancer patients. This latest data builds on a string of recent successes for Silexion, including its September 24 announcement of results from the Phase 2 trial for its first-generation product, LODER™, which showed significant improvements in tumor resectability among non-resectable pancreatic cancer patients. Alongside the new preclinical results, Silexion has recently reported plans to begin toxicology studies for SIL-204 in preparation for Phase 2/3 clinical trials expected to commence in the first half of 2026. The company is also expanding the application of its siRNA technology to colorectal cancer models, reflecting its broader ambitions to target multiple KRAS-driven cancers, which are notoriously difficult to treat with conventional therapies. While stock price has pulled back since premarket, The spike in Silexion’s market activity as marked by these record high volumes (according to market data) may highlight the growing market interest in the company’s novel approach to tackling cancers with high unmet medical needs, particularly its focus on KRAS mutations, which are common across a variety of aggressive cancers, including pancreatic and colorectal cancer. Silexion’s continued momentum in the precision oncology space potentially positions it as a leading player in the development of next-generation RNAi therapies. With its promising pipeline and recent positive developments, the company seems to be gaining attention as it advances toward clinical trials that could offer new hope for patients battling some of the deadliest cancers. Click here to read Silexion's full announcement *** This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [https://justpaste.it/ab9dn/pdf]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

October 01, 2024 11:47 AM Eastern Daylight Time

Article thumbnail News Release

drive21, Van Wagner Collaborate to Elevate In-Venue Branding and Fan Engagement Across College Athletics

drive21

drive21, a leader in experiential design and marketing solutions, today announced a strategic relationship with leading collegiate athletics marketing agency, Van Wagner to become a preferred experiential graphic design and implementation provider for Van Wagner. Van Wagner is recognized for its expertise in collegiate sponsorship sales and multi-media rights and will collaborate with drive21 to redefine branding strategies, drive revenue growth, and create Name, Image and Likeness (NIL) execution opportunities in the collegiate sports industry. Through this relationship, Van Wagner’s collegiate clients will be afforded advantageous pricing and access to drive21’s suite of services to provide innovative branding and design solutions across their venues; driving innovative solutions that bridge the gap between brand aspirations and reality, creating immersive environments that resonate with audiences and drive tangible business results. "This relationship represents a significant step forward in our mission to transform sports and entertainment venues into impactful environments that are also powerful marketing tools," said Warren Godridge, drive21 Founder and President. "By collaborating with Van Wagner, we can leverage our creativity and expertise to deliver a consistent brand experience across all venues, enhancing the value for brands, universities, and fans alike." “Traditional approaches often focus solely on aesthetics and overlook the potential to maximize partnership, sponsorship and NIL opportunities, leaving untapped value on the table” said John Libro, Head of Sports and Entertainment at drive21. “Working with Van Wagner College will allow us to push the boundaries of experiential design and transform collegiate athletic facilities into dynamic revenue-generating tools that engage fans and drive real business growth.” This relationship may also offer an even more comprehensive solution to collegiate clients by providing new NIL revenue streams. Through this collaboration with drive21, a portion of the facility’s expenditure can be reallocated to the universities’ NIL efforts. This allows universities to offer a more engaging experience for athletes and fans while creating dynamic environments supporting athletic performance, fan engagement and brand partnerships. "drive21’s ability to seamlessly integrate brand experiences into our facilities is a game-changer for our clients,” said Mark Donley, Chief Revenue Officer at Van Wagner College. “Through our arrangement with drive21, our university clients have an opportunity to access the expertise of drive21 to not only enhance their facilities but also ensure a consistent and high-quality experience for a variety of initiatives at an advantageous rate. It's truly a win-win-win scenario." The first major joint effort was a collaboration at Florida International University for the brand implementation of the newly named Pitbull Stadium. drive21 and Van Wagner played a key role in creating cohesive branding for the first college athletic venue named after a musician, exampling the transformative potential of experiential design and strategic branding. To learn more about the partnership, or drive21’s sports, entertainment and hospitality solutions, please visit www.drive21.com. About drive21 drive21 elevates the sports, entertainment, and hospitality industries by delivering one-of-a-kind branded venue experiences. A leader in experiential design and marketing solutions, drive21 bridges the gap between imagination and reality to deliver functional and impactful environments through design, fabrication, implementation, and holistic project management. Servicing organizations including MLB, MLS and NCAA institutions, drive21 helps its clients maximize partnership and sponsorship revenue and turns ordinary environments into extraordinary works of art. For more information, visit www.drive21.com. About Van Wagner Van Wagner is a leading sports advertising and entertainment agency with global expertise in filmed and live entertainment, sponsorship sales, multi-media rights, and aerial advertising. Van Wagner creates, advises, and sells for world-class teams, leagues, brands, and properties. An innovator in the sports and media business, Van Wagner is a global leader in high-impact broadcast visible signage throughout the MLB, NBA, NCAA, and international soccer, sponsorships sales, college multi-media rights, and in-venue content production at the world’s biggest sporting events. For more information, visit www.vanwagner.com. Contact Details Hot Paper Lantern Jackson Gaskins jgaskins@hotpaperlantern.com Company Website https://drive21.com

September 25, 2024 08:00 AM Eastern Daylight Time

Article thumbnail News Release

AI Unpacks Generational Stereotypes, Highlighting Key Differences, but Beer Bridges the Gap

AIport

What happens when you ask generative AI models to depict Baby Boomers, Gen X, Millennials, and Gen Z? You might expect tech-challenged Boomers and avocado-loving Millennials. But what you get is far more interesting and in some cases, unexpected. A joint research project conducted by AIport and Turing Post last month analyzed over 1200 AI-generated images across four different models—Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG. The findings have revealed both familiar stereotypes and surprising quirks about how AI perceives these generations. Sad Boomers, Happy Zoomers? Contrary to the carefree Boomer stereotype, AI models like Midjourney depict Baby Boomers as introspective, or even somber, often bundled up and gazing wistfully into the distance—a reflection, perhaps, of their disillusionment with the unfulfilled ideals of the 1960s cultural revolution. However, the ERNIE-ViLG model, likely trained on datasets with a more collectivist cultural slant, shows 93% of Boomers smiling. This fascinating contrast underscores the cultural differences embedded in different AI models. Meanwhile, Gen Z’s images are vibrant and diverse, reflecting their reputation as a generation that embraces individuality, inclusivity, and self-expression. The AI-generated images depict Zoomers in colorful, highly detailed scenarios, making them the most visually distinct generation in the study. Generations Through the AI Lens The research explored how generations are portrayed in five key aspects of life: identity, relationships, work, lifestyle, and consumer habits. The AI models revealed consistent patterns and stereotypes; for example, males predominated in the depictions of Boomers and Gen Xers across all four models, while many images of Millennials and Zoomers showed greater diversity and more female representation. Surprisingly, Gen X appears to be the least well-understood generation by AI, characterized by fewer defining features compared to all other generations, likely due to the limited amount of training data available. The one stereotypical Gen X leitmotif that AI consistently identifies is their fondness for flannel shirts—an unmistakable symbol of the 1990s grunge scene worn by Gen Xers who were rebellious teenagers and young adults during that era. As for one (un)expected commonality… It’s beer. Whether they’re Millennials job-hopping or Boomers reminiscing about the good old days, AI consistently showed beer in 34% of the produced images across all generations. Prompt Engineering and AI Insights The prompts for this research were carefully crafted to avoid bias, using neutral phrases like "A Millennial at work" or "A Boomer relaxing." The results offer a telling look at how generative AI models mirror societal stereotypes, often shaped by the data they're trained on. These findings open the door to deeper discussions on how AI reflects, and sometimes distorts, cultural narratives. "Whether we think we can learn about generations from these images depends upon how confident we feel that the training data that went in is an accurate image of the self identity of a group,” explains Senior Engineer and Sociologist Stephanie Kirmer, who analyzed the findings. “For the younger sets, I don’t think we can know how much of it is media representation created by people outside the group versus how much is selfie-style personal expression. Some of what we’re getting, especially for the older groups who don’t contribute as much self-generated visual media online, is perceptions of that group from advertising and media, which we know has inherent flaws." About the Study The study examined the outputs of four globally recognized generative AI models, each with distinct aesthetic and cultural nuances, providing a comprehensive look at how each generation is portrayed visually. The selected models included Stable Diffusion, Midjourney, YandexART, and ERNIE-ViLG, offering diverse perspectives from different regions across the globe. Conclusion Whether confirming or contradicting societal stereotypes, AI-generated images provide a fascinating snapshot of how technology interprets generational differences. The fact that beer remains a unifying theme across all four models shows that, no matter our age, some things—like enjoying a cold one—transcend generational divides. To learn more about the project, visit https://www.aigenerations.tech/. Hero images for the media: Google Drive Link About AIport AIport is an emerging community of AI/ML enthusiasts and practitioners with a goal of providing a truly global view of the AI/ML/DS landscape. https://www.blog.aiport.tech/ About Turing Post Turing Post is everything you need to make smarter decisions about AI. https://www.turingpost.com/ Contact Details Nick Leighton nick.leighton@nettresultsllc.com Company Website https://www.aigenerations.tech/

September 23, 2024 10:00 AM Eastern Daylight Time

Article thumbnail News Release

Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian

Global Markets News

Summit Therapeutics (NASDAQ: SMMT) recently captured headlines with the release of its Phase 3 data for ivonescimab, a targeted NSCLC therapy that has generated substantial buzz. The results from its trial conducted in China showed a dramatic 49% reduction in the risk of disease progression or death compared to Merck’s Keytruda, signaling a potentially disruptive force in NSCLC treatment. However, the news wasn’t without its concerns—since the trial data originates from China, there are questions about its applicability to broader, global populations. As noted by BMO Capital Markets’ Evan Seigerman: “Results may or may not be generalizable beyond the China-focused patient population initially assessed.” Despite this, Summit’s valuation has risen by over 100%, now approximating $19 billion. With such a high valuation, the company could see limited room for further significant gains, leading many in the industry to explore other emerging opportunities in precision oncology. Alongside Summit, there are quite a few other players in the field. Some if these companies have even already shown promising initial results and could see similar success in the future if they were to report positive results. These emerging players are worth watching for those interested in following precision oncology drug candidates and pipelines. Among them are precision oncology innovators such as Silexion Therapeutics, Nuvectis Pharma, and Scorpion Therapeutics, which we discuss below. Silexion Therapeutics: Disrupting the KRAS-Driven Cancer Space Silexion Therapeutics (NASDAQ: SLXN) is another under-the-radar player in the precision oncology space, with a focus on KRAS-driven cancers—a notoriously difficult target in oncology. While current small-molecule KRAS inhibitors are making progress, they are often limited to specific mutations, such as KRAS G12C, which accounts for a small percentage of cancers. Silexion’s RNA interference (RNAi) approach offers a broader solution, targeting a wider spectrum of KRAS mutations, particularly in pancreatic cancer, one of the deadliest and most treatment-resistant cancers. At the heart of Silexion’s approach is its LODER™ platform, which delivers siRNA directly to the tumor site, silencing KRAS mutations at the genetic level. This localized delivery not only increases efficacy by concentrating the treatment in the tumor, but it also reduces systemic side effects. Silexion’s next-generation candidate, SIL-204, is an optimized siRNA formulation designed to target pan-KRAS G12x mutations, positioning it to treat a broader range of KRAS-driven cancers beyond pancreatic cancer, such as lung and colorectal cancers. In Phase 2 trials for locally advanced pancreatic cancer, Silexion's LODER™ platform showed a 9.3-month improvement in overall survival when combined with standard chemotherapy. Additionally, the objective response rate (ORR) increased from 20% with chemotherapy alone to 55% with the combination, and in some cases, tumors that were initially non-resectable became operable after treatment with LODER™. These results are especially encouraging given the limited options available for pancreatic cancer patients. SIL-204, is expected to enter Phase 2/3 clinical trials in 2025-2026. What makes Silexion particularly intriguing is its current market valuation. Valued at aproximatly just ~$9 million following its SPAC merger, the company’s valuation could be perceived as low when compared to some of its peers, especially given its innovative technology and promising clinical achievements. Some have wondered whether this low valuation has more to do with dynamics post-SPAC companies. If Silexion can report positive results in its later-stage trials, the company’s outlook could dramatically improve, reflecting the potential of its RNAi-based platform. Like NXP900, SIL-204 could potentially have vast applications across multiple KRAS-driven cancer types, making Silexion a company to watch closely as it advances through clinical development. Nuvectis Pharma: Targeting NSCLC and Beyond by Inhibiting SRC/YES1 Kinases Nuvectis Pharma (NASDAQ: NVCT) has been quietly making strides in the precision oncology sector, developing innovative therapies aimed at overcoming treatment resistance in hard-to-treat cancers. Its lead candidate, NXP900, targets NSCLC by inhibiting the SRC/YES1 kinases, which play critical roles in cancer cell survival and resistance to current therapies. This approach positions NXP900 as a potential game-changer in the treatment of NSCLC, particularly in patients who have developed resistance to EGFR and ALK inhibitors, such as AstraZeneca’s Tagrisso and Novartis’ Alecensa. NXP900 is still in the early stages of clinical development, currently undergoing Phase 1 trials. However, preclinical studies have already shown that it has strong anti-tumor activity in resistant NSCLC models. Even more promising is its potential application beyond NSCLC. Like Summit's ivonescimab, NXP900 focuses on resistance, but it also has broader applications due to its ability to target multiple cancer types driven by SRC/YES1 pathways. This versatility makes it a promising asset not just for NSCLC but also for other difficult-to-treat cancers like squamous cell carcinomas. In addition to NXP900, Nuvectis is advancing NXP800, another precision oncology candidate that is further along in the clinical development process. NXP800 is currently in Phase 1b trials, targeting ARID1a-mutated cancers such as ovarian and endometrial cancers. The early clinical data for NXP800 is promising, showing positive responses in patients with platinum-resistant ovarian cancer. With two strong candidates in the pipeline, Nuvectis is positioning itself as a formidable player in the precision oncology landscape. As Summit’s ivonescimab continues to gain attention, Nuvectis’ earlier-stage NXP900, with its NSCLC focus and beyond, could see similar success in the future if clinical results continue to trend positively. Scorpion Therapeutics: Pioneering Mutant-Selective Therapies Scorpion Therapeutics is redefining the frontier of precision oncology with its focus on delivering highly selective small molecules targeting validated and previously undruggable cancer mutations. Its lead candidate, STX-478, is a mutant-selective, allosteric PI3Kα inhibitor currently in Phase 1/2 trials for advanced solid tumors. Early data presented at the ESMO Congress 2024 highlighted its potential, with STX-478 demonstrating a 23% overall response rate in breast cancer and a 21% response rate across all tumor types, positioning it as a potentially best-in-class PI3Kα inhibitor. STX-478 is notable for its ability to spare wild-type PI3Kα activity in normal tissues, avoiding the toxicities seen with previous PI3Kα inhibitors, such as hyperglycemia and rash. Tumor reductions were seen in 72% of patients treated with STX-478 as a monotherapy, with circulating tumor DNA levels dropping in 86% of patients. This mutant-selective precision could help overcome the limitations of existing PI3Kα inhibitors, which have struggled with dose-limiting toxicities. In July 2024, Scorpion raised $150 million in a Series C financing round, co-led by Frazier Life Sciences and Lightspeed Venture Partners. The additional funding will support the advancement of STX-478 and other pipeline assets, positioning Scorpion for further clinical success. Scorpion’s pipeline includes a broad range of wholly-owned compounds that target both validated and novel cancer targets, positioning the company for future expansion into larger patient populations. As STX-478 progresses through clinical development, Scorpion is poised to become a significant player in the precision oncology space, making it another company worth watching closely. Optimistic Outlook for Precision Oncology The precision oncology space is experiencing a golden era of innovation, with companies like Summit Therapeutics, Nuvectis Pharma, Silexion Therapeutics, and Scorpion Therapeutics leading the charge. As the focus shifts towards targeted therapies that address resistance mechanisms, the market is increasingly favoring companies with novel approaches and broad applications. Summit’s meteoric rise has shown that there is tremendous potential for companies that can demonstrate efficacy in overcoming cancer resistance. While Summit has already captured much of the current attention, companies like Nuvectis, Silexion, and Scorpion, with their earlier-stage pipelines, offer exciting opportunities for the industry to keep a close eye on. As these companies continue to report clinical data and advance through trials, the potential for breakthroughs in treating some of the most difficult cancers grows stronger. With targeted therapies offering the possibility of overcoming resistance without the need for chemotherapy, the future of cancer treatment looks brighter than ever. For those in the oncology space, keeping a close eye on emerging players like Nuvectis, Silexion, and Scorpion could lead to transformative developments as the field of precision oncology continues to evolve. * * * This update may include speculative forward looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. the BioTech and Pharma industries are volatile and risky and readers are advised to seek out preffesional advice in the relevent feilds from licensed profesionals. This update is for informational purposes only and is not intended to serve as financial, investment or any form of professional advice, recommendation or endorsement. Please review the full documentation detailing financial compensation disclosures and disclaimers the article is subject to. [ https://justpaste.it/ch2qt/pdf ]. Global Markets News Network is a commercial digital brand compensated to provide coverage of news and developments related to innovative companies as detailed in the full documentation and it is thus subject to conflicts of interest. Contact Details News Coverage ronald@futuremarketsresearch.com

September 19, 2024 07:45 AM Eastern Daylight Time

12345 ... 86